Label (71610 810 32)
Not available.*
Entresto Tablet, Film Coated
Product Images NDC 71610-810
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Entresto (NDC 71610-810). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Aphena (Aphena)
Valsartan Structural Formula (Entresto 01)
Figure 1: Effect Of Entresto On Pharmacokinetics Of Coadministered Drugs (Entresto 02)
This text provides information on the geometric mean ratio and 90% confidence interval for several drugs when coadministered with other drugs. The drugs mentioned include Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil. The text suggests a comparison of the drugs' effects when taken together.*
Figure 2: Pharmacokinetics Of Entresto In Specific Populations (Entresto 03)
Figure 3: Kaplan-meier Curves For The Primary Composite Endpoint (a), Cardiovascular Death (b), And Heart Failure Hospitalization (c) (Entresto 04)
Figure 4: Primary Composite Endpoint (cv Death Or Hf Hospitalization) (Subgroup Analysis)
This dataset provides detailed information on various subgroups within a population, including demographics such as age, gender, weight, race, region, and medical conditions like diabetes, hypertension, atrial fibrillation, and heart failure. The data also presents the percentage of individuals in each category and compares outcomes related to the use of medications like Entresto and Enalapril, showcasing hazard ratios for each. These statistics can be valuable for analyzing the impact of different factors on health outcomes in a specific population.*
Figure 5: Mean Number Of Events Over Time For The Primary Composite Endpoint Of Total Hf Hospitalizations And Cv Death (Entresto 09)
Total Heart Failure Hospitalizations and Cardiovascular Death in PARAGON-HF study with Valsartan and ENTRESTO. The mean number of events per 100 patients is 8. The graph shows the time since randomization (days) and the corresponding data points related to the study.*
Figure 6: Primary Composite Endpoint Of Total Hf Hospitalizations And Cv Death – Subgroup Analysis (paragon-hf) (Entresto 10)
Figure 7: Treatment Effect For The Composite Endpoint Of Time To First Hf Hospitalization Or Cv Death By Lvef In Paradigm-hf And Paragon-hf (Entresto 11)
This text shows a comparison of Hazard Ratios for ENTRESTO versus enalapril and valsartan in the PARADIGM-HF and PARAGON-HF trials based on left ventricular ejection fraction values. The graph displays the hazard ratios at various left ventricular ejection fraction percentages. This information is valuable for evaluating the efficacy of ENTRESTO in comparison to traditional heart failure medications.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
